Cargando…

Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD–Driven AML

The protein tyrosine phosphatase SHP2 is crucial for oncogenic transformation of acute myeloid leukemia (AML) cells expressing mutated receptor tyrosine kinases. SHP2 is required for full RAS-ERK activation to promote cell proliferation and survival programs. Allosteric SHP2 inhibitors act by stabil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pfeiffer, Anamarija, Franciosa, Giulia, Locard-Paulet, Marie, Piga, Ilaria, Reckzeh, Kristian, Vemulapalli, Vidyasiri, Blacklow, Stephen C., Theilgaard-Mönch, Kim, Jensen, Lars J., Olsen, Jesper V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Molecular Cell Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177641/ https://www.ncbi.nlm.nih.gov/pubmed/35311954 http://dx.doi.org/10.1158/0008-5472.CAN-21-0548

Ejemplares similares

Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition
por: LaRochelle, Jonathan R., et al.
Publicado: (2018)

Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors
por: Franciosa, Giulia, et al.
Publicado: (2023)

Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML
por: Popescu, Bogdan, et al.
Publicado: (2023)

Time-resolved phosphoproteomics reveals scaffolding and catalysis-responsive patterns of SHP2-dependent signaling
por: Vemulapalli, Vidyasiri, et al.
Publicado: (2021)

Selective inhibition of leukemia-associated SHP2(E69K) mutant by the allosteric SHP2 inhibitor SHP099
por: Sun, X, et al.
Publicado: (2018)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

The Protein Tyrosine Phosphatase, Shp2, Positively Contributes to FLT3-ITD-Induced Hematopoietic Progenitor Hyperproliferation and Malignant Disease In Vivo
por: Nabinger, Sarah C., et al.
Publicado: (2012)

Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia
por: Richine, Briana M., et al.
Publicado: (2016)

Monobody Inhibitor Selective to the Phosphatase Domain of SHP2 and its Use as a Probe for Quantifying SHP2 Allosteric Regulation
por: Sha, Fern, et al.
Publicado: (2023)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2
por: Pádua, Ricardo A. P., et al.
Publicado: (2018)

An allosteric interaction controls the activation mechanism of SHP2 tyrosine phosphatase
por: Anselmi, Massimiliano, et al.
Publicado: (2020)

Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML
por: Vachhani, Pankit, et al.
Publicado: (2016)

Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

Cigarette smoke exposure accelerates AML progression in FLT3-ITD models
por: Figueroa, Mary, et al.
Publicado: (2023)

A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment
por: Long, Jun, et al.
Publicado: (2023)

FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML
por: Kivioja, Jarno, et al.
Publicado: (2021)

Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
por: Castaño-Bonilla, Tamara, et al.
Publicado: (2021)

Evaluation of FLT3-ITD Mutations and MDR1 Gene Expression in AML Patients
por: Yazdandoust, Ehsan, et al.
Publicado: (2022)

Allosteric inhibition of SHP2 uncovers aberrant TLR7 trafficking in aggravating psoriasis
por: Zhu, Yuyu, et al.
Publicado: (2021)

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD(+) AML cell growth
por: Weir, Mark C., et al.
Publicado: (2017)

CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
por: Waldeck, Silvia, et al.
Publicado: (2020)

Shp2 Knockdown and Noonan/LEOPARD Mutant Shp2–Induced Gastrulation Defects
por: Jopling, Chris, et al.
Publicado: (2007)

Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia
por: Al-Jamal, Hamid Ali Nagi, et al.
Publicado: (2015)

Maturation State-Specific Alternative Splicing in FLT3-ITD and NPM1 Mutated AML
por: Wojtuszkiewicz, Anna, et al.
Publicado: (2021)

Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML
por: Schmidt, Franziska, et al.
Publicado: (2022)

Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach
por: Pugliese, Giusj Monia, et al.
Publicado: (2023)

Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation
por: Bogdanov, Konstantin, et al.
Publicado: (2023)

Functions of Shp2 in cancer
por: Zhang, Jie, et al.
Publicado: (2015)

Sidestepping SHP2 inhibition
por: Popescu, Bogdan, et al.
Publicado: (2023)

Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
por: Stockard, Bradley, et al.
Publicado: (2018)

Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2019)

Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors
por: Xu, Xiaozheng, et al.
Publicado: (2021)

Inhibition of SHP2 and SHP1 Protein Tyrosine Phosphatase Activity by Chemically Induced Dimerization
por: Buck, Sara J. S., et al.
Publicado: (2022)

Exploration of T cell immune responses by expression of a dominant-negative SHP1 and SHP2
por: Taylor, Julia, et al.
Publicado: (2023)

The Allosteric Site on SHP2’s Protein Tyrosine Phosphatase Domain is Targetable with Druglike Small Molecules
por: Marsh-Armstrong, Brennan, et al.
Publicado: (2018)

Phosphotyrosine couples peptide binding and SHP2 activation via a dynamic allosteric network
por: Marasco, Michelangelo, et al.
Publicado: (2021)

SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses
por: Christofides, Anthos, et al.
Publicado: (2022)

Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML
por: Stirewalt, D L, et al.
Publicado: (2014)

Petromurin C Induces Protective Autophagy and Apoptosis in FLT3-ITD-Positive AML: Synergy with Gilteritinib
por: Ha, You Na, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3fn4qmk5ruif1cuvrscq728jd2